Marshall Wace LLP Lowers Stock Holdings in STAAR Surgical (NASDAQ:STAA)

Marshall Wace LLP decreased its stake in STAAR Surgical (NASDAQ:STAA - Free Report) by 55.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 152,553 shares of the medical instruments supplier's stock after selling 192,023 shares during the quarter. Marshall Wace LLP owned approximately 0.31% of STAAR Surgical worth $3,706,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in STAA. Illinois Municipal Retirement Fund increased its holdings in STAAR Surgical by 8.3% in the 4th quarter. Illinois Municipal Retirement Fund now owns 30,144 shares of the medical instruments supplier's stock worth $732,000 after acquiring an additional 2,318 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its stake in shares of STAAR Surgical by 9.7% during the 4th quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 39,500 shares of the medical instruments supplier's stock valued at $959,000 after buying an additional 3,500 shares in the last quarter. HighTower Advisors LLC raised its stake in STAAR Surgical by 42.6% during the 4th quarter. HighTower Advisors LLC now owns 12,956 shares of the medical instruments supplier's stock valued at $315,000 after purchasing an additional 3,871 shares during the period. LPL Financial LLC grew its holdings in STAAR Surgical by 45.3% during the 4th quarter. LPL Financial LLC now owns 15,994 shares of the medical instruments supplier's stock valued at $388,000 after buying an additional 4,989 shares in the last quarter. Finally, Barclays PLC grew its holdings in STAAR Surgical by 5.5% during the 4th quarter. Barclays PLC now owns 96,769 shares of the medical instruments supplier's stock valued at $2,351,000 after buying an additional 5,062 shares in the last quarter. Institutional investors own 96.70% of the company's stock.

Insiders Place Their Bets

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 36,532 shares of the company's stock in a transaction on Friday, February 14th. The stock was acquired at an average price of $15.49 per share, for a total transaction of $565,880.68. Following the completion of the transaction, the insider now directly owns 11,289,437 shares of the company's stock, valued at approximately $174,873,379.13. This represents a 0.32 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought 1,742,581 shares of company stock valued at $28,407,543 over the last three months. 1.00% of the stock is owned by company insiders.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock traded down $0.02 on Thursday, reaching $18.24. The company had a trading volume of 78,927 shares, compared to its average volume of 792,967. The firm's 50-day moving average price is $17.29 and its two-hundred day moving average price is $22.57. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $49.86. The firm has a market cap of $899.89 million, a price-to-earnings ratio of -44.40 and a beta of 0.75.

Analysts Set New Price Targets

STAA has been the subject of a number of research reports. BTIG Research lowered shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 12th. Piper Sandler dropped their price objective on shares of STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating for the company in a report on Wednesday, February 12th. Jefferies Financial Group cut STAAR Surgical from a "buy" rating to a "hold" rating in a report on Wednesday, February 12th. William Blair lowered STAAR Surgical from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus reduced their price objective on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, STAAR Surgical currently has an average rating of "Hold" and an average price target of $24.25.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.